大麻素受体
大麻素
神经保护
内大麻素系统
大麻
神经科学
大麻
大麻酚
临床试验
医学
大麻素受体激动剂
药理学
兴奋剂
受体
生物信息学
精神科
心理学
生物
内科学
植物
作者
Mayur Bhimrao Kale,Mohit D. Umare,Nitu L. Wankhede,Rohitas Deshmukh,Vikrant Abbot,Md. Khalid Anwer,Brijesh Gulabrao Taksande,Aman Babanrao Upaganlawar,Milind Janrao Umekar,Seema Ramniwas,Monica Gulati,Rashmi Arora,Tapan Behl
标识
DOI:10.2174/0113816128318194240918113954
摘要
has served diverse roles, from medicinal applications to recreational use. Despite its extensive historical use, only a fraction of its components have been explored until recent times. The therapeutic potential of Cannabis and its constituents has garnered attention, with suggestions for treating various conditions such as Parkinson's disease, epilepsy, Alzheimer's disease, and other neurological disorders. Recent research, particularly on animal experimental models, has unveiled the neuroprotective properties of cannabis. This neuroprotective effect is orchestrated through numerous G protein-coupled receptors (GPCRs) and the two cannabinoid receptors, CB1 and CB2. While the capacity of cannabinoids to safeguard neurons is evident, a significant challenge lies in determining the optimal cannabinoid receptor agonist and its application in clinical trials. The intricate interplay of cannabinoids with the endocannabinoid system, involving CB1 and CB2 receptors, underscores the need for precise understanding and targeted approaches. Unravelling the molecular intricacies of this interaction is vital to harness the therapeutic potential of cannabinoids effectively. As the exploration of cannabis components accelerates, there is a growing awareness of the need for nuanced strategies in utilizing cannabinoid receptor agonists in clinical settings. The evolving landscape of cannabis research presents exciting possibilities for developing targeted interventions that capitalize on the neuroprotective benefits of cannabinoids while navigating the complexities of receptor specificity and clinical applicability.
科研通智能强力驱动
Strongly Powered by AbleSci AI